SLEEP APNEA AND CORONARY ARTERY DISEASE

Robert G. Hooper, Sept 2003 (Scottsdale Sleep Center)

THE METABOLIC SYNDROME (ref 1,2,3 & 4)

It is a suspected prodrome of arteriosclerotic vascular disease
It consist of: Insulin resistance, reduced levels of high-density lipoprotein
(HDL) cholesterol, a high triglyceride levels and central obesity.
It has also been called syndrome X or the insulin resistance syndrome

Its cause is not known, but a genetic component is suspected

SLEEP APNEA AND THE METABOLIC SYNDROME (ref 5 & 6)

Patients with Sleep Apnea have the parameters of the METABOLIC SYNDROME which varies directly with the severity of sleep apnea

Treatment with Nasal CPAP improves or reverses the findings of the METABOLIC SYNDROME

C REACTIVE PROTEIN AND SLEEP APNEA (ref 7 & 8)

Elevations of C-reactive protein is a recognized risk factor for CAD C-reactive protein is elevated in newly diagnosed Sleep Apnea C-reactive protein improves with CPAP treatment of Sleep Apnea

SLEEP AND THE METABOLIC SYNDROME (ref 9))

Effect of limiting normal sleep

The effect of normal sleep on metabolic parameters is not established

The biologic sleep requirement for health is not known

Suspected to be 8 hours (Mother's report - not a double blinded study) Studies compared eight hours sleep verses six and four hours under controlled conditions

Measurement of C-reactive protein and metabolic syndrome parameters at baseline and after sleep restriction.

Result

Normal individuals developed the parameters of the METABOLIC SYNDROME with sleep restriction

Return to eight hours of sleep reverses the findings.

CONCLUSIONS

SLEEP APNEA IS ASSOCIATED WITH THE METABOLIC SYNDROME AND ELEVATED C-REACTIVE PROTEIN
TREATMENT WITH CPAP IMPROVES OR REVERSES THE FINDINGS
REDUCE SLEEP PRODUCES THE METABOLIC SYNDROME

(Sept 2003)

REFERENCES:

THE METABOLIC SYNDROME

- Wilson PFW, Dannel WB, Sibershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999;159:1104-1109
- 2) Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607
- Haffner SM, valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes. 1992;41:715-722.

THE METABOLIC SYNDROME AND SLEEP APNEA

- 4) Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol. 1999;83:25F-29F
- 5) Vgontzas AN, Bixler EO, Chrousos GP. Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J Intern Med. 2003;254:32-44.
- 6) Yokoe T, Minoguchi K, Matsuo H et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003;107:1129-34.

C-REACTIVE PROTEIN AND SLEEP APNEA

- 7) Shamsuzzaman AS, Winnicki M, Lanfranchi et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation. 2002;105:2462-2464
- 8) Yoke T, Minoguchi K, Matsuo H et al. Elevated levels of C-reactive protein and interleukin-6 in patient with obstructive sleep apnea syndrom are decreased by nasal continuous positive airway pressure. Circulation. 2003;107:1129-1134.

SLEEP RESTRICTION AND METABOLIC SYNDROME

 Alexander Vgontzas and Virend K. Somers. Oral presentations at American Academy of Sleep Medicine meetings June 2003